Bharat Biotech's homegrown COVID-19 vaccine has shown an interim vaccine efficacy of 81% in late-stage clinical trials, the Indian company said on Wednesday.
The interim analysis was based on 43 recorded cases of COVID-19 in the trial of 25,800 participants, conducted in partnership with the Indian government's medical research body.
Thirty-six of the 43 cases were recorded in participants who received a placebo, compared with seven cases in people who were given the Bharat Biotech vaccine, pointing to an efficacy rate of 80.6%, the company said.
India had approved the vaccine, branded COVAXIN, in January without late-stage efficacy data, raising questions about its effectiveness.
India's vaccination drive, currently underway, includes COVAXIN and a vaccine developed by Oxford University and AstraZeneca.
Earlier this week, Indian Prime Minister Narendra Modi was inoculated with the first dose of COVAXIN.
The Republican-controlled US Senate passed President Donald Trump's tax and spending bill on Tuesday, signing off on a massive package that would enshrine many of his top domestic priorities into law while adding $3.3 trillion to the national debt.
More than a thousand schools were closed in France on Tuesday and the top floor of the Eiffel Tower was shut to tourists as a severe heatwave continued to grip Europe, triggering health alerts across the region.
Thailand's Constitutional Court on Tuesday suspended Prime Minister Paetongtarn Shinawatra from duty pending a case seeking her dismissal, in a major setback for a government under fire on multiple fronts and fighting for its survival.
President Donald Trump has signed an executive order terminating a US sanctions programme on Syria, allowing an end to the country's isolation from the international financial system and building on Washington's pledge to help it rebuild after a devastating civil war.